Compulsory licensing: A misused and abused international trade law

To maintain our position as the world ’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing abuse – along with price controls and other trade barriers – threatens to chip away at our foothold and erode the resources companies c an invest in the next generation of medicines.

Source: The Catalyst - May 16, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Access Intellectual Property trade Source Type: news